首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

2106274

穿戴式注射器市場：按裝置類型、自動化程度、用途、治療領域和地區分類的趨勢和預測（至 2035 年）

Wearable Injectors Market by Type of Device, Type of Degree of Automation, Type of Usability, Type of Therapeutic Area, and Geographical Regions - Trends and Forecast Till 2035

出版日期: 2026年07月22日 | 出版商:

Roots Analysis | 英文 702 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

穿戴式注射器市場：市場概覽

根據 Roots Analysis 的研究，全球穿戴式注射器市場規模預計將從今年的 65 億美元成長到 2035 年的 130 億美元，在預測期內（到 2035 年）的複合年成長率為 7.4%。

穿戴式注射器市場：成長與趨勢

穿戴式注射器（也稱為貼片幫浦）是一種貼附於皮膚的醫療設備，旨在皮下持續數分鐘至數小時輸送大劑量或高黏度藥物。這些注射器使患者能夠在臨床環境之外自行注射複雜的生技藥品和治療慢性疾病的藥物，從而減少頻繁就醫的需要。鑑於糖尿病、類風濕性關節炎和心血管疾病等慢性疾病的盛行率不斷上升，隨著人口老化，醫療保健系統持續面臨巨大壓力。

根據美國疾病管制與預防中心（CDC）統計，美國約有190萬人被診斷出罹患癌症，預計到2030年，醫療保健費用將超過2,300億美元。此外，2024年將有超過85萬人死於心血管疾病，預計到2050年，心血管疾病的治療費用將接近2兆美元。慢性病的治療需要頻繁就醫，不僅增加了治療成本，也導致病患治療順從性下降。

為了應對這項挑戰，製藥公司和醫療設備製造商正加大對以患者為中心的給藥技術的投入，以提高患者居家治療的依從性和臨床療效。穿戴式注射器簡化了高劑量生技藥品的基礎劑量、大劑量投藥或持續給藥，其內建的安全功能可減少針刺傷，並增強患者居家使用的信心。 BD公司主導的聯合產品試驗就是一個例證，該試驗使用BD Libertas穿戴式式注射器進行複雜生技藥品的皮下注射，這反映出業界對大容量、便捷的給藥系統日益成長的信心。

穿戴式裝置在居家醫療環境中皮下給藥方面已被廣泛應用。這種向自我給藥模式的轉變促使設備開發商和製藥公司在其產品中添加先進功能。這些先進功能包括基於人工智慧的演算法、整合行動應用程式、智慧健康監測、劑量提醒以及語音或視覺劑量確認。隨著藥物輸送設備的持續技術創新和穿戴式注射器接受度的不斷提高，預計市場將在預測期內穩步成長。

穿戴式注射器市場

市場規模和機會分析根據以下參數進行分類：

依設備類型

貼片幫浦
點滴幫浦

按自動化級別

自動/智慧型泵
手動幫浦

依用途類型

一次性的
可重複使用（含一次性零件）

按治療區域

腫瘤性疾病
心血管疾病
自體免疫疾病
神經系統疾病
其他疾病

按地區

北美洲
美國
加拿大
墨西哥
歐洲
法國
德國
英國
義大利
西班牙
其他歐洲國家
亞洲
中國
印度
日本
其他亞洲地區
中東和北非
埃及
以色列
沙烏地阿拉伯
拉丁美洲
阿根廷
巴西

穿戴式注射器市場：主要細分市場

輸液幫浦持續推動穿戴式注射器市場的發展。

根據 Roots Analysis 的市場評估，輸液幫浦目前佔最大的市場佔有率，約佔整個市場的 95%。預計在整個預測期內，該細分市場將保持其主導地位，這主要歸功於這些設備具有劑量精準、可程式設計給藥功能以及經臨床驗證的療效。除了在胰島素依賴型患者中的廣泛應用外，完善的醫保報銷機制和醫生的高度信任也鞏固了其在該細分市場領導地位。

另一方面，預計在預測期內，貼片幫浦細分市場將實現最高成長率。這一成長主要得益於居家醫療和遠距醫療發展的整體趨勢，尤其是在糖尿病和癌症等慢性病領域。

北美保持市場領先地位

根據該公司的市場預測，北美預計將保持主導地位直至2035年，佔全球近70%的市場。該地區的領先地位得益於其完善的醫療保健基礎設施、糖尿病和其他慢性病的高發病率、有利的保險報銷機制以及對先進藥物輸送技術的早期應用。此外，強勁的醫療費用支出、有利於創新醫療設備的法規環境以及領先的穿戴式注射器製造商的存在，都持續增強了該地區的競爭力。數位健康解決方案的日益普及以及越來越多患者尋求居家疾病管理，預計也將推動北美市場的長期成長。

亞太地區正在崛起成為成長最快的區域市場。

根據該公司的市場預測，亞太地區預計將在預測期內實現最高的複合年成長率，並成為全球成長最快的市場。這一強勁成長主要得益於中國和印度等主要經濟體快速的都市化、不斷壯大的中產階級、可支配收入的增加以及慢性病患病率的上升。

此外，人口結構的變化，特別是老年人口的成長，正在催生對便捷的居家給藥解決方案的持續需求。政府旨在加強醫療基礎設施、擴大保險覆蓋範圍、促進國內醫療設備製造以及改善先進醫療技術可及性的各項舉措，正在進一步加速市場成長。此外，生技藥品的日益普及、人們對自我給藥療法的認知不斷提高以及數位醫療解決方案的採用，預計也將支撐該地區市場的長期成長。

本報告對全球穿戴式注射器市場進行了分析，提供了概述、背景、市場影響因素分析、市場規模趨勢和預測、按各個細分市場和地區/主要國家進行的詳細分析、競爭格局以及主要公司的概況。

章節概要
藥物輸送裝置概述
傳統腸外給藥裝置
- 針刺傷
- 發生狀況和成本負擔
- 預防針刺傷
- 政府關於預防事故的法規
自我管理設備的出現
可用的自行注射裝置
- 預填充式注射器
- 筆式注射器
- 無針注射器
- 自動噴油器
- 穿戴式注射器
監管方面的考慮
- 醫療設備
- 藥品和醫療設備組合產品
前景

第7章非胰島素藥物用穿戴注射器：市場概覽

章節概要
市場狀況
開發者趨勢

第8章：非胰島素類藥物的藥物和醫療設備組合：市場概覽

章節概要
市場狀況
開發者趨勢

第9章穿戴式胰島素注射器：市場概覽

章節概要
市場狀況
開發者趨勢

第10章：產品競爭力分析

章節概要
前提條件/關鍵參數
調查方法
產品競爭力分析

第11章：開發穿戴式注射器的公司：公司簡介

章節概要
公司正在研發用於非胰島素藥物的穿戴式注射器
- CCBio
- E3D Elcam Drug Delivery Devices
- Enable Injections
- Gerresheimer
- Sonceboz
- Weibel CDS (Acquired by SHL Medical)
- West Pharmaceuticals
公司正在研發用於胰島素的穿戴式注射器
- CeQur
- Debiotech
- Eli Lilly
- Insulet
- Medtronic
- Medtrum Technologies
- PharmaSens
- Roche
- SOOIL Development

第12章藥物與醫療設備的組合：器材概況

章節概要
Neulasta®（Pegfilgrastim）OnPro™套件
D-mine(R)泵
Lasix(R) ONYU
LUTREPULSE(R)系統
ND0612L 新一代貼片幫浦
名稱未公開（由飛利浦醫療科技公司開發）
FUROSCIX(R)
SMT-201泵
SMT-301泵
ULTOMRIS(R) 智慧劑量注射器（ravulizumab-cwvz）
EMPAVELI(R) 噴油器
SKYRIZI(R) 體內注射器（risankizumab）
VYALEV(TM) 泵浦（磷卡比多巴/磷左旋多巴）
UDENYCA® 體外注射器
ONAPGO(TM)
Remunity(R)泵
G-Lasta(R) BodyPod
Sarclisa（isatuximab）體外注射器

第13章夥伴關係與合作

章節概要
合作模式
穿戴式注射器：夥伴關係與合作

第14章主要收購目標

章節概要
研究範圍和調查方法
評分標準和關鍵先決條件
潛在收購目標：開發非胰島素藥物輸送裝置的公司。
潛在收購目標：開發胰島素藥物輸送裝置的公司。
結論

第15章專利分析

章節概要
研究範圍和調查方法
穿戴式注射器：專利分析
穿戴式注射器：專利基準分析
專利評估
被引用次數最多的專利

第16章穿戴式注射器：前景看好的候選藥物

章節概要
非處方藥
處於臨床階段的藥物

第17章臨床試驗分析

章節概要
研究範圍和調查方法
穿戴式注射器：臨床試驗分析

第18章：資金籌措與投資分析

章節概要
資金籌措類型
穿戴式注射器：資金籌措與投資分析

第19章 SWOT 分析

章節概要
SWOT分析
穿戴式注射器：未來的成長機遇

第20章案例研究：CMO在醫療設備開發供應鏈中的作用

章節概要
設備開發供應鏈
合約行銷組織（CMO）在醫療設備開發中的作用
行銷長名單
醫療設備設計開發服務供應商

第21章：醫療設備監管與報銷制度的現狀

章節概要
醫療設備的一般規定和報銷指南
北美監管和報銷機制
歐洲的監管和報銷機制現狀
亞太地區及世界其他地區的監管和報銷情況

第22章市場影響分析：促進因素、阻礙因素、機會與挑戰

章節概要
市場促進因素
市場限制因素
市場機遇
市場挑戰
結論

第23章：非胰島素藥物穿戴式注射器的市場

章節概要
關鍵假設和調查方法
全球非胰島素藥物穿戴式注射器市場：歷史趨勢與預測（價值）
全球非胰島素藥物穿戴式注射器市場：歷史趨勢與預測（銷售量）
主要市場區隔

第24章：非胰島素藥物穿戴式注射器市場：依設備類型分類

章節概要
關鍵假設和調查方法
按設備類型（以金額為準）
按設備類型（基於數量）
- 穿戴貼片幫浦市場：歷史趨勢與預測
- 穿戴式輸液幫浦市場：歷史趨勢與預測
數據三角測量與檢驗

第25章：非胰島素藥物穿戴式注射器市場：依使用方式分類

章節概要
關鍵假設和調查方法
非胰島素藥物穿戴式注射器市場：依應用領域（以金額為準）
非胰島素藥物穿戴式注射器市場：按應用領域（按銷售量）分類
- 一次性穿戴式注射器：歷史趨勢與預測（以數量計）
- 可重複使用/一次性組件式穿戴注射器：歷史趨勢和預測（按數量計）
數據三角測量與檢驗

第26章：非胰島素藥物穿戴式注射器市場：依治療領域分類

章節概要
關鍵假設和調查方法
非胰島素藥物穿戴式注射器市場：按治療領域分類（以金額為準）
非胰島素藥物穿戴式注射器市場：依治療領域（按銷售量）分類
- 癌症
- 心血管疾病
- 自體免疫疾病
- 神經系統疾病
- 非胰島素相關疾病
數據三角測量與檢驗

第27章：非胰島素藥物穿戴式注射器市場：依地區分類

章節概要
關鍵假設和調查方法
非胰島素藥物穿戴式注射器市場：按地區分類（以金額為準）
非胰島素藥物穿戴式注射器市場：按地區（按銷售）分類
- 北美洲
- 歐洲
- 亞洲
- 拉丁美洲
- 中東和北非
市場動態評估
- 滲透成長（PG）矩陣
- 市場波動分析
數據三角測量與檢驗

第28章：穿戴式胰島素注射器市場

章節概要
關鍵假設和調查方法
全球穿戴式胰島素注射器市場：歷史趨勢與預測（以金額為準）
全球穿戴式胰島素注射器市場：歷史趨勢與預測（按銷量計）
主要市場區隔

第29章：穿戴式胰島素注射器市場：依設備類型分類

章節概要
關鍵假設和調查方法
胰島素穿戴式注射器市場：以設備類型分類（以金額為準）
穿戴式胰島素注射器市場：依裝置類型分類（以銷售量計）
- 貼片幫浦：過去趨勢與預測
- 輸液幫浦：過去趨勢與預測
數據三角測量與檢驗

第30章：穿戴式胰島素注射器市場：依自動化程度分類

章節概要
關鍵假設和調查方法
胰島素穿戴式注射器市場：依自動化程度（以金額為準）分類
胰島素穿戴式注射器市場：依自動化程度（以銷售量計）分類
- 自動/智慧型穿戴注射器：過去趨勢與預測
- 手動穿戴注射器：過去趨勢與預測
數據三角測量與檢驗

第31章：穿戴式胰島素注射器市場：按地區分類

章節概要
關鍵假設和調查方法
穿戴式胰島素注射器市場：按地區分類（以金額為準）
穿戴式胰島素注射器市場：按地區（按銷售）分類
- 北美洲
- 歐洲
- 亞洲
- 拉丁美洲
- 中東和北非
市場動態評估
- 滲透成長（PG）矩陣
- 市場波動分析
數據三角測量與檢驗

第32章結論

第33章高階主管洞察

第34章附錄一：表格形式數據

第35章附錄二：公司與組織列表

簡介目錄圖表

Product Code: RA100656

WEARABLE INJECTORS MARKET: OVERVIEW

As per Roots Analysis, the global wearable injectors market is estimated to grow from USD 6.5 billion in the current year to USD 13.0 billion by 2035, at a CAGR of 7.4% during the forecast period, till 2035.

Wearable Injectors Market: Growth and Trends

Wearable injectors, also known as on-body patch pumps, are skin-adhered devices designed to deliver large-volume or high-viscosity drugs subcutaneously over extended durations, ranging from minutes to several hours. These injectors enable patients to self-administer complex biologics and chronic disease therapies outside clinical settings, eliminating the need for frequent clinical visits. Given the growing prevalence of chronic disorders, including diabetes, cancer, rheumatoid arthritis, and cardiovascular conditions, healthcare systems continue to witness immense pressure amid an aging population.

As per the report of Centers for Disease Control and Prevention, nearly 1.9 million people are diagnosed with Cancer in the US, and the cost of care is estimated to reach over USD 230 billion by 2030. Moreover, more than 8,50,000 died due to heart stroke in 2024 and the cost of managing cardiovascular diseases is projected to reach nearly USD 2 trillion by 2050. Chronic disease management requires frequent visits to hospitals which not only increase treatment costs but also reduce patient's adherence to treatment.

To address this burden, pharmaceutical and medical device companies are increasingly investing in patient-centric drug delivery innovations that improve treatment adherence and clinical outcomes at home. Wearable injectors simplify the administration of sustained basal, bolus, or continuous doses of high-volume biologics, while built-in safety features reduce needlestick injuries and improve patient confidence for home use. This shift is exemplified by recent developments such as BD's pharma-sponsored combination product trial using the BD Libertas wearable injector for subcutaneous delivery of complex biologics, reflecting growing industry confidence in large-volume, patient-ready delivery systems.

Wearable devices have gained wide acceptance for subcutaneous drug administration in home-care settings. This shift toward self-administration has pushed device developers and pharmaceutical companies to add advanced features to their offerings. These advanced features include AI-based algorithms, companion mobile apps, smart health monitoring, dosing reminders, and audible or visual delivery confirmation. Continuous innovation in drug delivery devices, along with growing acceptance of wearable injectors, is expected to support steady market growth over the forecast period.

Growth Drivers: Strategic Enablers of Market Expansion

The wearable injectors market is experiencing robust growth, driven by the increasing prevalence of chronic diseases, including diabetes, cancer, rheumatoid arthritis, and cardiovascular disorders, alongside a growing geriatric population. Rising demand for long-term, precise drug administration is accelerating the adoption of wearable drug delivery systems that improve treatment adherence and therapeutic outcomes. The expanding use of biologics and the shift toward patient-centric healthcare are further supporting market growth. Additionally, the increasing preference for self-administration and home-based care is driving the adoption of wearable patch and infusion injectors, reducing reliance on healthcare facilities while enhancing patient convenience. Advancements in digital health technologies, such as Bluetooth and Wi-Fi connectivity, AI-enabled dose management, smartphone integration, and remote patient monitoring, are further improving device functionality and enabling personalized, connected healthcare, thereby strengthening the long-term growth prospects of the wearable injectors market.

Market Challenges: Critical Barriers Impeding Progress

Despite its strong growth prospects, the wearable injectors market faces several challenges that may limit broader adoption. High device costs, driven by advanced technologies and specialized materials, remain a significant barrier, particularly in regions with limited reimbursement support and high out-of-pocket healthcare expenses. Additionally, stringent regulatory requirements and lengthy approval processes increase development costs and delay product commercialization. Limited awareness and inadequate training among patients and healthcare professionals further increase the risk of improper device usage and suboptimal treatment outcomes, especially in elderly populations and resource-constrained settings. Addressing these cost, reimbursement, regulatory, and educational challenges will be critical to accelerating market adoption and realizing the full commercial potential of wearable injector technologies.

Wearable Injectors Market: Key Insights

The report delves into the current state of the wearable injectors market and identifies potential growth opportunities within the industry. Some key findings include:

Device manufacturers in the wearable injectors market predominantly rely on direct sales to reach hospitals, pharmaceutical companies, and specialty channels. This model currently limits the visibility that third-party distributors have into wearable injector commercialization, despite their established reach into home care and retail pharmacy networks.
Specialty pharmacies and third-party logistics (3PL) providers are emerging as the primary distribution intermediaries for wearable injector-based biologic therapies, rather than traditional pharmaceutical wholesalers. McKesson Plasma and Biologics illustrates this shift, offering dedicated specialty distribution and cold chain services tailored to biologics and other high-touch drug categories.
Distributors seeking entry into the wearable injectors market must demonstrate specialized cold chain and handling infrastructure. Cardinal Health's 3PL Services unit reflects this requirement, having built dedicated capabilities for temperature-controlled storage and transport of biologics and injectable therapies.
Direct-to-patient and home delivery models, integrated with telehealth and e-prescribing, are reshaping the distributor value proposition from pure product movement toward end-to-end patient onboarding, device training, and adherence support.
Accreditation from bodies such as URAC and the Accreditation Commission for Health Care (ACHC) is increasingly required for distributors and specialty pharmacies seeking inclusion in limited-distribution networks for wearable injector-paired biologics.
Rising demand for self-injection systems, driven in part by GLP-1 receptor agonist therapies, is prompting contract development and manufacturing organizations to integrate device assembly and distribution capabilities directly into their service offerings, blurring the boundary between manufacturing and distribution partners.
Regulatory reform of pharmacy benefit managers, including the Consolidated Appropriations Act of 2026 mandating rebate pass-through and pricing transparency, is altering the economics of specialty distribution in the US and encouraging manufacturers to diversify beyond PBM-affiliated pharmacies.
Distributors handling wearable injectors increasingly compete on value-added services such as patient hub support, device training, and connected app enablement, rather than on logistics efficiency alone, mirroring a shift already observed across the broader specialty biologics distribution market.
Consolidation among large-scale specialty distributors and 3PLs is raising barriers to entry for smaller regional players. At the same time, the shift toward decentralized, home-based biologic administration is creating openings for niche distributors with condition-specific or region-specific expertise.

Wearable Injectors Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Device

Patch Pumps
Infusion Pumps

By Degree of Automation

Automated / Smart Pumps
Manual Pumps

By Usability

Disposable
Reusable (Disposable Components)

By Therapeutic Area

Oncological Disorders
Cardiovascular Disorders
Autoimmune Disorders
Neurological Disorders
Other Disorders

By Geographical Regions

North America
US
Canada
Mexico
Europe
France
Germany
UK
Italy
Spain
Rest of Europe
Asia
China
India
Japan
Rest of Asia
Middle East and North Africa
Egypt
Israel
Saudi Arabia
Latin America
Argentina
Brazil

Wearable Injectors Market: Key Segments

Infusion Pumps Continue to Lead the Wearable Injectors Market

Based on our market assessment, infusion pumps currently constitute the largest segment of the insulin wearable injectors market, accounting for approximately 95% of the overall market share. The segment is expected to retain its dominant position throughout the forecast period, primarily due to the high level of dosing precision, programmable drug delivery capabilities, and proven clinical effectiveness offered by these devices. Their widespread adoption across insulin-dependent patient populations, coupled with established reimbursement pathways and strong physician confidence, continues to reinforce their market leadership.

In contrast, the patch pumps segment is anticipated to register the fastest growth rate over the forecast period. This growth is driven by the increasing demand for patient-centric drug delivery solutions that enable convenient, discreet, and hands-free self-administration in home-care settings. Their compact, skin-adhered design enhances patient mobility, improves treatment adherence, and aligns with the broader industry shift toward decentralized healthcare and remote disease management, particularly for chronic conditions such as diabetes and oncology.

North America Maintains Market Leadership

According to our market projections, North America is expected to maintain its leadership in the wearable injectors market through 2035, accounting for nearly 70% of the global market share. The region's dominance is underpinned by a well-established healthcare infrastructure, a high prevalence of diabetes and other chronic diseases, favorable reimbursement frameworks, and the early adoption of advanced drug delivery technologies. Furthermore, strong healthcare expenditure, a supportive regulatory environment for innovative medical devices, and the presence of leading wearable injector manufacturers continue to reinforce the region's competitive position. Increasing integration of digital health solutions and growing patient preference for home-based disease management are also expected to sustain long-term market growth across North America.

Asia-Pacific Emerges as the Fastest-Growing Regional Market

According to our market projections, the Asia-Pacific's wearable injectors market is expected to register the highest CAGR during the forecast period, positioning the region as the fastest-growing market globally. This robust growth is being driven by rapid urbanization, expanding middle-class populations, rising disposable incomes, and the increasing prevalence of chronic diseases across major economies such as China and India.

In addition, demographic shifts, particularly the growing geriatric population, are creating sustained demand for convenient, home-based drug delivery solutions. Government initiatives aimed at strengthening healthcare infrastructure, expanding insurance coverage, promoting domestic medical device manufacturing, and improving access to advanced healthcare technologies are further accelerating market expansion. The increasing penetration of biologics, coupled with rising awareness of self-administration therapies and the adoption of digital health solutions, is also expected to support long-term market growth across the region.

Oncological Disorders Account for the Largest Share of the Non-Insulin Segment

Based on our analysis, the oncological disorders segment currently accounts for the largest share of the non-insulin wearable injectors market and is expected to maintain its market leadership throughout the forecast period. This dominance is primarily driven by the increasing global incidence of cancer, the expanding adoption of biologics and monoclonal antibody therapies, and the growing preference for subcutaneous administration of high-volume therapeutics. Wearable injectors are particularly well suited for oncology applications, as they enable the controlled and prolonged delivery of complex drug formulations, improve patient comfort, reduce infusion chair time, and facilitate the transition of cancer treatment from hospital settings to home-based care.

Example Players in Wearable Injectors Market

Becton Dickinson (BD)
Enable Injections
Insulet
Medtronic
Tandem Diabetes Care
West Pharmaceutical Services
Ypsomed

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Chief Executive Officer, Small Company, US
Chief Executive Officer, Mid-Sized Company, US
Chief Executive Officer, Small Company, Denmark
Former President and Chief Executive Officer, Mid-Sized Company, US
Vice President and Chief Scientist, Large Company, Israel
Former Vice President and General Manager, Biologics, Very Large Company, US
Anonymous, Large Company, Switzerland
Engineering Project Manager / Senior System Engineer, Small Company, Switzerland
Vice President, Marketing and Alliance Management, Mid-Sized Company, US

WEARABLE INJECTORS MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the wearable injectors market, focusing on key market segments, including type of device, degree of automation, usability, therapeutic area, and geographical regions.
Insulin Wearable Injectors Landscape: A detailed assessment of the overall insulin wearable injectors market landscape, featuring information on several relevant parameters, such as type of device, degree of automation, compatibility with high-viscosity drugs, and regulatory approvals. Additionally, it features detailed analysis of device manufacturers, based on parameters such as year of establishment, company size (based on employee count), and location of headquarters.
Non-Insulin Wearable Injectors Landscape: A detailed assessment of the overall non-insulin wearable injectors market landscape, featuring information on parameters such as usability, therapeutic area, drug compatibility, and status of development. Additionally, it features detailed analysis of device developers, based on parameters such as year of establishment, company size, and location of headquarters.
Company Profiles: In-depth profiles of prominent players engaged in offering wearable injectors, featuring information on their year of establishment, location of headquarters, company size (in terms of number of employees), management team, portfolio, and key initiatives.
Patent Analysis: An analysis of the patents filed / granted related to wearable injector devices, based on parameters such as type of patent, patent application year, patent publication year, patent jurisdiction, CPC symbols, type of applicant, patent benchmarking, and patent valuation.
Recent Developments: A detailed analysis of the various recent developments in this industry, including partnerships and collaborations, funding and investments, and global events, based on several relevant parameters.
Porter's Five Forces Analysis: A qualitative analysis of five competitive forces in this domain, namely, threats of new entrants, bargaining power of buyers, bargaining power of providers, threat of substitute products, and rivalry among existing competitors.
Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

Which are the leading companies in the wearable injectors market?
Which region dominates the wearable injectors market?
What are the key trends observed in the wearable injectors market?
What factors are likely to influence the evolution of this market?
What are the primary challenges faced by wearable injector developers?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
The report allows for more effective communication with the audience and in building strong business relations.

ADDITIONAL BENEFITS

Complementary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated Report if the Report is 6-12 Months Old or Older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Introduction to Drug Delivery Devices
6.3. Conventional Parenteral Drug Delivery Devices
- 6.3.1. Needlestick Injuries
- 6.3.2. Incidence and Cost Burden
- 6.3.3. Prevention of Needlestick Injuries
- 6.3.4. Government Legislations for the Prevention of Needlestick Injuries
6.4. Emergence of Self-Administration Devices
- 6.4.1. Key Driving Factors
  - 6.4.1.1. Rising Burden of Chronic Diseases
  - 6.4.1.2. Healthcare Cost Savings
  - 6.4.1.3. Need for Immediate Treatment in Emergency Situations
  - 6.4.1.4. Growing Injectable Drugs Market
  - 6.4.1.5. Need for Improving Medication Adherence
6.5. Available Self-Injection Devices
- 6.5.1. Prefilled Syringes
- 6.5.2. Pen-Injectors
- 6.5.3. Needle-Free Injectors
- 6.5.4. Autoinjectors
- 6.5.5. Wearable Injectors
6.6. Regulatory Considerations
- 6.6.1. Medical Devices
- 6.6.2. Drug Device Combination Products
6.7. Future Perspectives

7. WEARABLE INJECTORS FOR NON-INSULIN DRUGS: MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Wearable Injectors for Non-Insulin Drugs: Overall Market Landscape
- 7.2.1. Analysis by Type of Device
- 7.2.2. Analysis by Status of Development
- 7.2.3. Analysis by Type of Drug Delivery
- 7.2.4. Analysis by Usability
- 7.2.5. Analysis by Drug Reservoir Volume
- 7.2.6. Analysis by Type of Drug Molecule
- 7.2.7. Analysis by Type of Dose
- 7.2.8. Analysis by Dose of Drug
- 7.2.9. Analysis by Mode of Injection
- 7.2.10. Analysis by Therapeutic Area
- 7.2.11. Analysis by Type of Drug Container
- 7.2.12. Analysis by Mode of Drug Filling
7.3. Wearable Injectors for Non-Insulin Drugs: Developer Landscape
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Location of Headquarters
- 7.3.4. Leading Players: Analysis by Number of Wearable Injectors Developed for Non-Insulin

8. DRUG DEVICE COMBINATIONS FOR NON-INSULIN DRUGS: MARKET LANDSCAPE

8.1. Chapter Overview
8.2. Drug Device Combinations for Non-Insulin Drugs: Overall Market Landscape
- 8.2.1. Analysis by Type of Device
- 8.2.2. Analysis by Status of Development
- 8.2.3. Analysis by Type of Drug Delivery
- 8.2.4. Analysis by Usability
- 8.2.5. Analysis by Drug Reservoir Volume
- 8.2.6. Analysis by Type of Drug Molecule
- 8.2.7. Analysis by Type of Dose
- 8.2.8. Analysis by Dose of Drug
- 8.2.9. Analysis by Mode of Injection
- 8.2.10. Analysis by Therapeutic Area
- 8.2.11. Analysis by Type of Drug Container
- 8.2.12. Analysis by Mode of Drug Filling
8.3. Drug Device Combinations for Non-Insulin Drugs: Developer Landscape
- 8.3.1. Analysis by Year of Establishment
- 8.3.2. Analysis by Company Size
- 8.3.3. Analysis by Location of Headquarters
- 8.3.4. Device Developers: Distribution by Number of Drug Device Combination Developed

9. WEARABLE INJECTORS FOR INSULIN: MARKET LANDSCAPE

9.1. Chapter Overview
9.2. Wearable Injectors for Insulin: Overall Market Landscape
- 9.2.1. Analysis by Type of Device
- 9.2.2. Analysis by Status of Development
- 9.2.3. Analysis by Type of Insulin Delivery
- 9.2.4. Analysis by Type of Automated Insulin Delivery
- 9.2.5. Analysis by Type of Connectivity Feature
- 9.2.6. Analysis by Type of Feedback Mechanism
- 9.2.7. Analysis by Waterproofing Capability
- 9.2.8. Analysis by Usability
- 9.2.9. Analysis by Period of Use
- 9.2.10. Analysis by Type of Advanced Feature
- 9.2.11. Analysis by Type of Drug Container
- 9.2.12. Analysis by Mode of Drug Filling
- 9.2.13. Analysis by Type of Dose
- 9.2.14. Analysis by Type of Diabetes
- 9.2.15. Analysis by Availability of Connectivity Feature
9.3. Wearable Injectors for Insulin: Developer Landscape
- 9.3.1. Analysis by Year of Establishment
- 9.3.2. Analysis by Company Size
- 9.3.3. Analysis by Location of Headquarters
- 9.3.4. Leading Players: Analysis by Number of Wearable Injectors Developed for Insulin

10. PRODUCT COMPETITIVENESS ANALYSIS

10.1. Chapter Overview
10.2. Assumptions / Key Parameters
10.3. Methodology
10.4. Product Competitiveness Analysis
- 10.4.1. Product Competitiveness Analysis: Wearable Injectors for Non-Insulin Drugs
- 10.4.2. Product Competitiveness Analysis: Drug Device Combinations for Non-Insulin Drugs
- 10.4.3. Product Competitiveness Analysis: Wearable Injectors for Insulin

11. WEARABLE INJECTOR DEVELOPERS: COMPANY PROFILES

11.1. Chapter Overview
11.2. Key Players Developing Wearable Injectors for Non-Insulin
- 11.2.1. CCBio
  - 11.2.1.1. Company Overview
  - 11.2.1.2. Product Portfolio
  - 11.2.1.3. Recent Developments and Future Outlook
- 11.2.2. E3D Elcam Drug Delivery Devices
- 11.2.3. Enable Injections
- 11.2.4. Gerresheimer
- 11.2.5. Sonceboz
- 11.2.6. Weibel CDS (Acquired by SHL Medical)
- 11.2.7. West Pharmaceuticals
11.3. Key Players Developing Wearable Injectors for Insulin
- 11.3.1. CeQur
- 11.3.2. Debiotech
- 11.3.3. Eli Lilly
- 11.3.4. Insulet
- 11.3.5. Medtronic
- 11.3.6. Medtrum Technologies
- 11.3.7. PharmaSens
- 11.3.8. Roche
- 11.3.9. SOOIL Development

12. DRUG-DEVICE COMBINATIONS: DEVICE PROFILES

12.1. Chapter Overview
12.2. Neulasta(R) (pegfilgrastim) OnPro(TM) Kit
12.3. D-mine(R) Pump
12.4. Lasix(R) ONYU
12.5. The LUTREPULSE(R) System
12.6. ND0612L Next generation patch pump
12.7. Unnamed (Developed by Phillips Medisize)
12.8. FUROSCIX(R)
12.9. SMT-201 Pump
12.10. SMT-301 Pump
12.11. ULTOMRIS(R) Smartdose Injector (ravulizumab-cwvz)
12.12. EMPAVELI(R) Injector
12.13. SKYRIZI(R) On Body Injector (risankizumab)
12.14. VYALEV(TM) Pump (foscarbidopa and foslevodopa)
12.15. UDENYCA(R) on-body injector
12.16. ONAPGO(TM)
12.17. Remunity(R) Pump
12.18. G-Lasta(R) BodyPod
12.19. Sarclisa (isatuximab) On-Body Injector

13. PARTNERSHIPS AND COLLABORATIONS

13.1. Chapter Overview
13.2. Partnership Models
13.3. Wearable Injectors: Partnerships and Collaborations
- 13.3.1. Analysis by Year of Partnership
- 13.3.2. Analysis by Type of Partnership
- 13.3.3. Analysis by Year and Type of Partnership
- 13.3.4. Analysis by Type of Partner
- 13.3.5. Analysis by Type of Device
- 13.3.6. Most Active Players: Analysis by Number of Partnerships
- 13.3.7. Analysis by Geography
  - 13.3.7.1. Local and International Agreements
  - 13.3.7.2. Intercontinental and Intracontinental Agreements

14. KEY ACQUISITION TARGETS

14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Scoring Criteria and Key Assumptions
14.4. Potential Acquisition Targets: Non-Insulin Drug Delivery Device Developers
14.5. Potential Acquisition Targets: Insulin Drug Delivery Device Developers
14.6. Concluding Remarks

15. PATENT ANALYSIS

15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Wearable Injectors: Patent Analysis
- 15.3.1. Analysis by Type of Patent
- 15.3.2. Analysis by Patent Publication Year
- 15.3.3. Analysis by Patent Application Year
- 15.3.4. Analysis of Granted Patents and Patent Applications by Publication Year
- 15.3.5. Analysis by Jurisdiction
- 15.3.6. Analysis by Type of Applicant
- 15.3.7. Analysis by Patent Age
- 15.3.8. Analysis by CPC Symbol
- 15.3.9. Most Active Players: Analysis by Number of Patents
15.4. Wearable Injectors: Patent Benchmarking Analysis
- 15.4.1. Analysis by Patent Characteristics
15.5. Patent Valuation
15.6. Leading Patents by Number of Citations

16. WEARABLE INJECTORS: LIKELY DRUG CANDIDATES

16.1. Chapter Overview
16.2. Marketed Drugs
- 16.2.1. Most Likely Candidates for Delivery via Wearable Injectors
- 16.2.2. Likely Candidates for Delivery via Wearable Injectors
- 16.2.3. Less Likely Candidates for Delivery via Wearable Injectors
- 16.2.4. Least Likely Candidates for Delivery via Wearable Injectors
16.3. Clinical Stage Drugs
- 16.3.1. Most Likely Candidates for Delivery via Wearable Injectors
- 16.3.2. Likely Candidates for Delivery via Wearable Injectors
- 16.3.3. Less Likely Candidates for Delivery via Wearable Injectors
- 16.3.4. Least Likely Candidates for Delivery via Wearable Injectors

17. CLINICAL TRIAL ANALYSIS

17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Wearable Injectors: Clinical Trial Analysis
- 17.3.1. Analysis by Trial Recruitment Status
- 17.3.2. Analysis by Trial Registration Year
- 17.3.3. Analysis of Enrolled Patient Population by Trial Registration Year
- 17.3.4. Analysis by Trial Phase
- 17.3.5. Analysis of Enrolled Patient Population by Trial Phase
- 17.3.6. Analysis by Trial Registration Year and Trial Recruitment Status
- 17.3.7. Analysis by Study Design
- 17.3.8. Analysis by Type of Sponsor / Collaborator
- 17.3.9. Analysis by Therapeutic Area
- 17.3.10. Most Active Players: Analysis by Number of Registered Trials
- 17.3.11. Most Popular Wearable Injectors: Analysis by Number of Registered Trials
- 17.3.12. Analysis by Geography
  - 17.3.12.1. Analysis by Trial Recruitment Status and Geography
  - 17.3.12.2. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography

18. FUNDING AND INVESTMENT ANALYSIS

18.1. Chapter Overview
18.2. Types of Funding
18.3. Wearable Injectors: Funding and Investment Analysis
- 18.3.1. Analysis by Year of Funding
- 18.3.2. Analysis of Amount Invested by Year
- 18.3.3. Analysis by Type of Funding
- 18.3.4. Analysis by Type of Device
- 18.3.5. Analysis of Amount Invested by Year and Type of Funding
- 18.3.6. Analysis of Amount Invested by Type of Device
- 18.3.7. Analysis by Target Disease Indication
- 18.3.8. Most Active Players: Analysis by Number of Funding Instances
- 18.3.9. Most Active Players: Analysis by Amount Invested
- 18.3.10. Leading Investors: Analysis by Number of Funding Instances
- 18.3.11. Analysis by Geography

19. SWOT ANALYSIS

19.1. Chapter Overview
19.2. SWOT Analysis
- 19.2.1. Strengths
- 19.2.2. Weaknesses
- 19.2.3. Opportunities
- 19.2.4. Threats
19.3. Wearable Injectors: Future Growth Opportunities
- 19.3.1. Rising Focus on Self-Administration of Drugs
- 19.3.2. Possibility of Integration with Mobile Applications
- 19.3.3. Potential Life Cycle Management Tool
- 19.3.4. Potential Usability for Multiple Therapeutic Areas

20. CASE STUDY: ROLE OF CONTRACT MANUFACTURING ORGANIZATIONS IN DEVICE DEVELOPMENT SUPPLY CHAIN

20.1. Chapter Overview
20.2. Device Development Supply Chain
20.3. Role of Contract Manufacturing Organizations (CMOs) in Device Development
20.4. List of CMOs
- 20.4.1. Geographical Distribution of CMOs
20.5. Medical Devices Design and Development Service Providers

21. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

21.1. Chapter Overview
21.2. General Regulatory and Reimbursement Guidelines for Medical Devices
21.3. Regulatory and Reimbursement Landscape in North America
- 21.3.1. The US Scenario
  - 21.3.1.1. Regulatory Authority
  - 21.3.1.2. Review / Approval Process
  - 21.3.1.3. Reimbursement Landscape
    - 21.3.1.3.1. Payer Mix
    - 21.3.1.3.2. Reimbursement Process
- 21.3.2. The Canadian Scenario
  - 21.3.2.1. Regulatory Authority
  - 21.3.2.2. Review / Approval Process
  - 21.3.2.3. Reimbursement Landscape
    - 21.3.2.3.1. Payer Mix
    - 21.3.2.3.2. Reimbursement Process
- 21.3.3. The Mexican Scenario
  - 21.3.3.1. Regulatory Authority
  - 21.3.3.2. Review / Approval Process
  - 21.3.3.3. Reimbursement Landscape
    - 21.3.3.3.1. Payer Mix
21.4. Regulatory and Reimbursement Landscape in Europe
- 21.4.1. Overall Scenario
  - 21.4.1.1. Overall Regulatory Authority
  - 21.4.1.2. Overall Review / Approval Process
- 21.4.2. The UK Scenario
  - 21.4.2.1. Regulatory Authority
  - 21.4.2.2. Review / Approval Process
  - 21.4.2.3. Reimbursement Landscape
    - 21.4.2.3.1. Payer Mix
    - 21.4.2.3.2. Reimbursement Process
- 21.4.3. The French Scenario
  - 21.4.3.1. Regulatory Authority
  - 21.4.3.2. Review / Approval Process
  - 21.4.3.3. Reimbursement Landscape
    - 21.4.3.3.1. Payer Mix
    - 21.4.3.3.2. Reimbursement Process
- 21.4.4. The German Scenario
  - 21.4.4.1. Regulatory Authority
  - 21.4.4.2. Review / Approval Process
  - 21.4.4.3. Reimbursement Landscape
    - 21.4.4.3.1. Payer Mix
    - 21.4.4.3.2. Reimbursement Process
- 21.4.5. The Italian Scenario
  - 21.4.5.1. Regulatory Authority
  - 21.4.5.2. Review / Approval Process
  - 21.4.5.3. Reimbursement Landscape
    - 21.4.5.3.1. Payer Mix
    - 21.4.5.3.2. Reimbursement Process
- 21.4.6. The Spanish Scenario
  - 21.4.6.1. Regulatory Authority
  - 21.4.6.2. Review / Approval Process
  - 21.4.6.3. Reimbursement Landscape
    - 21.4.6.3.1. Payer Mix
    - 21.4.6.3.2. Reimbursement Process
21.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
- 21.5.1. The Australian Scenario
  - 21.5.1.1. Regulatory Authority
  - 21.5.1.2. Review / Approval Process
  - 21.5.1.3. Reimbursement Landscape
    - 21.5.1.3.1. Payer Mix
    - 21.5.1.3.2. Reimbursement Process
- 21.5.2. The Brazilian Scenario
  - 21.5.2.1. Regulatory Authority
  - 21.5.2.2. Review / Approval Process
  - 21.5.2.3. Reimbursement Landscape
    - 21.5.2.3.1. Payer Mix
    - 21.5.2.3.2. Reimbursement Process
- 21.5.3. The Chinese Scenario
  - 21.5.3.1. Regulatory Authority
  - 21.5.3.2. Review / Approval Process
  - 21.5.3.3. Reimbursement Landscape
    - 21.5.3.3.1. Payer Mix
    - 21.5.3.3.2. Reimbursement Process

22. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

22.1. Chapter Overview
22.2. Market Drivers
22.3. Market Restraints
22.4. Market Opportunities
22.5. Market Challenges
22.6. Conclusion

23. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 23.3.1. Scenario Analysis
  - 23.3.1.1. Conservative Scenario
  - 23.3.1.2. Optimistic Scenario
23.4. Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 23.4.1. Scenario Analysis
  - 23.4.1.1 Conservative Scenario
  - 23.4.1.2. Optimistic Scenario
23.5. Key Market Segmentations

24. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY TYPE OF DEVICE

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Value)
- 24.3.1. Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 24.3.2. Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
24.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Volume)
- 24.4.1. Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 24.4.2. Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
24.5. Data Triangulation and Validation

25. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY USABILITY

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Value)
- 25.3.1. Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 25.3.2. Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
25.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Volume)
- 25.4.1. Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 25.4.2. Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
25.5. Data Triangulation and Validation

26. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY THERAPEUTIC AREA

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Value)
- 26.3.1. Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 26.3.2. Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 26.3.3. Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 26.3.4. Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 26.3.5. Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
26.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Volume)
- 26.4.1. Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 26.4.2. Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 26.4.3. Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 26.4.4. Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 26.4.5. Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
26.5. Data Triangulation and Validation

27. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY GEOGRAPHICAL REGIONS

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Value)
- 27.3.1. Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 27.3.2. Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 27.3.3. Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 27.3.4. Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 27.3.5. Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
27.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Volume)
- 27.4.1. Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 27.4.2. Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 27.4.3. Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 27.4.4. Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 27.4.5. Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
27.5. Market Dynamics Assessment
- 27.5.1. Penetration Growth (P-G) Matrix
- 27.5.2. Market Movement Analysis
27.6. Data Triangulation and Validation

28. WEARABLE INJECTORS MARKET FOR INSULIN

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 28.3.1. Scenario Analysis
  - 28.3.1.1. Conservative Scenario
  - 28.3.1.2. Optimistic Scenario
28.4. Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 28.4.1. Scenario Analysis
  - 28.4.1.1. Conservative Scenario
  - 28.4.1.2. Optimistic Scenario
28.5. Key Market Segmentations

29. WEARABLE INJECTORS MARKET FOR INSULIN, BY TYPE OF DEVICE

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Wearable Injectors Market for Insulin: Distribution by Type of Device (By Value)
- 29.3.1. Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 29.3.2. Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
29.4. Wearable Injectors Market for Insulin: Distribution by Type of Device (By Volume)
- 29.4.1. Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 29.4.2. Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
29.5. Data Triangulation and Validation

30. WEARABLE INJECTORS MARKET FOR INSULIN, BY DEGREE OF AUTOMATION

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Value)
- 30.3.1. Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 30.3.2. Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
30.4. Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Volume)
- 30.4.1. Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 30.4.2. Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
30.5. Data Triangulation and Validation

31. WEARABLE INJECTORS MARKET FOR INSULIN, BY GEOGRAPHICAL REGIONS

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Value)
- 31.3.1. Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.1.1. Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.1.2. Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 31.3.2. Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.1. Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.2. Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.3. Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.4. Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.5. Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.2.6. Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 31.3.3. Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.3.1. Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.3.2. Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.3.3. Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.3.4. Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.3.5. Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 31.3.4. Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.4.1. Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.4.2. Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.4.3. Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
- 31.3.5. Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.5.1. Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.5.2. Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
  - 31.3.5.3. Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.4. Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Volume)
- 31.4.1. Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.1.1. Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.1.2. Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 31.4.2. Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.1. Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.2. Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.3. Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.4. Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.5. Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.2.6. Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 31.4.3. Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.3.1. Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.3.2. Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.3.3. Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.3.4. Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.3.5. Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 31.4.4. Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.4.1. Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.4.2. Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.4.3. Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
- 31.4.5. Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.5.1. Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.5.2. Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
  - 31.4.5.3. Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.5. Market Dynamics Assessment
- 31.5.1. Penetration Growth (P-G) Matrix
- 31.5.2. Market Movement Analysis
31.6. Data Triangulation and Validation

32. CONCLUDING INSIGHTS

33. EXECUTIVE INSIGHTS

34. APPENDIX I: TABULATED DATA

35. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

簡介目錄圖表

List of Tables

Table 7.1 Wearable Injectors for Non-Insulin Drugs: Information on Status of Development, Type of Device and Usability
Table 7.2 Wearable Injectors for Non-Insulin Drugs: Information on Type of Dose, Type of Drug Container and Mode of Drug Filling
Table 7.3 Wearable Injectors for Non-Insulin Drugs: Information on Container Volume, Route of Administration and Mode of Injection
Table 7.4 Wearable Injectors for Non-Insulin Drugs: Information on Mechanism of Action / Driving Force and Type of Technology
Table 7.5 Wearable Injectors for Non-Insulin Drugs: Information on Availability of Connectivity Feature and Type of Compatible Drug
Table 7.6 Wearable Injectors for Non-Insulin Drugs: Information on Compatibility with High Viscosity Drugs and Therapeutic Area
Table 7.7 Wearable Injectors for Non-Insulin Drugs: Information on Device Developer, Year of Establishment, Company Size, and Location of Headquarters
Table 8.1 Drug Device Combinations for Non-Insulin Drugs: Information on Status of Development, Type of Device and Usability
Table 8.2 Drug Device Combinations for Non-Insulin Drugs: Information on Type of Dose, Mode of Drug Filling, Type of Drug Container and Container Volume
Table 8.3 Drug Device Combinations for Non-Insulin Drugs: Information on Route of Administration, Mode of Injection and Type of Compatible Drug
Table 8.4 Drug Device Combinations for Non-Insulin Drugs: Information on Drug Delivery Technology, Mechanism of Action / Driving Force and Therapeutic Area
Table 8.5 Drug Device Combinations for Non-Insulin Drugs: Information on Device Developer, Year of Establishment, Company Size, and Location of Headquarters
Table 9.1 Wearable Injectors for Insulin: Information on Status of Development, Type of Device and Type of Insulin Delivery
Table 9.2 Wearable Injectors for Insulin: Information on Type of Automated Insulin Delivery, Type of Connectivity Feature and Type of Feedback Mechanism
Table 9.3 Wearable Injectors for Insulin: Information on Waterproofing Capability, Usability and Period of Use
Table 9.4 Wearable Injectors for Insulin: Information on Type of Advanced Feature, Type of Drug Container and Mode of Drug Filling
Table 9.5 Wearable Injectors for Insulin: Information on Type of Dose, Type of Diabetes and Availability of Connectivity Feature
Table 9.6 Wearable Injectors for Insulin: Information on Device Developer, Year of Establishment, Company Size, and Location of Headquarters
Table 11.1 Wearable Injector Developers: List of Companies Profiled
Table 11.2 CCBio: Company Overview
Table 11.3 CCBio: Device Portfolio
Table 11.4 CCBio: Recent Developments and Future Outlook
Table 11.5 E3D Elcam Drug Delivery Device: Company Overview
Table 11.6 E3D Elcam Drug Delivery Device: Device Portfolio
Table 11.7 E3D Elcam Drug Delivery Devices: Recent Developments and Future Outlook
Table 11.8 Enable Injections: Company Overview
Table 11.9 Enable Injections: Device Portfolio
Table 11.10 Enable Injections: Recent Developments and Future Outlook
Table 11.11 Gerresheimer: Company Overview
Table 11.12 Gerresheimer: Device Portfolio
Table 11.13 Gerresheimer: Recent Developments and Future Outlook
Table 11.14 Sonceboz: Company Overview
Table 11.15 Sonceboz: Device Portfolio
Table 11.16 Sonceboz: Recent Developments and Future Outlook
Table 11.17 Weibel CDS: Company Overview
Table 11.18 Weibel CDS: Device Portfolio
Table 11.19 Weibel CDS: Developments and Future Outlook
Table 11.20 West Pharmaceuticals: Company Overview
Table 11.21 West Pharmaceuticals: Device Portfolio
Table 11.22 West Pharmaceuticals: Developments and Future Outlook
Table 11.23 CeQur: Company Overview
Table 11.24 CeQur: Device Portfolio
Table 11.25 CeQur: Developments and Future Outlook
Table 11.26 Eli Lilly: Company Overview
Table 11.27 Eli Lilly: Device Portfolio
Table 11.28 Eli Lilly: Developments and Future Outlook
Table 11.29 Insulet: Company Overview
Table 11.30 Insulet: Device Portfolio
Table 11.31 Insulet: Developments and Future Outlook
Table 11.32 Medtronic: Company Overview
Table 11.33 Medtronic: Device Portfolio
Table 11.34 Medtronic: Developments and Future Outlook
Table 11.35 Medtrum Technologies: Company Overview
Table 11.36 Medtrum Technologies: Device Portfolio
Table 11.37 Medtrum Technologies: Developments and Future Outlook
Table 11.38 Roche: Company Overview
Table 11.39 Roche: Device Portfolio
Table 11.40 Roche: Developments and Future Outlook
Table 11.41 SOOIL Development: Company Overview
Table 11.42 SOOIL Development: Device Portfolio
Table 11.43 SOOIL Development: Developments and Future Outlook
Table 12.1 Drug Device Combination: 3 mL Micropump (Furosemide)
Table 12.2 Drug Device Combination: 3M hMTS (Adalimumab)
Table 12.3 Drug Device Combination: D-mine Pump (Apomorphine)
Table 12.4 Drug Device Combination: On-body Infusor (Furosemide)
Table 12.5 Drug Device Combination: Herceptin SC Injector (Herceptin)
Table 12.6 Drug Device Combination: ND0712H Belt Pump (Levodopa / Carbidopa)
Table 12.7 Drug Device Combination: ND0712L belt pump (Levodopa / Carbidopa)
Table 12.8 Drug Device Combination: ND0712L next generation patch pump (Levodopa / Carbidopa)
Table 12.9 Drug Device Combination: ND0801 (Apomorphine)
Table 12.10 Drug Device Combination: ND0901 (Levodopa / Carbidopa)
Table 12.11 Drug Device Combination: Neulasta Onpro On-Body Injector (Neulasta)
Table 12.12 Drug Device Combination: Pushtronex System (Repatha)
Table 12.13 Drug Device Combination: SMT-201 (Ketorolac)
Table 12.14 Drug Device Combination: SMT-301 (Bupivacaine)
Table 12.15 Drug Device Combination: The LUTREPULSE System (Lutrepulse)
Table 12.16 Drug Device Combination: Trevyent (Treprostinil)
Table 12.17 Drug Device Combination: Ultomris (Ravulizumab)
Table 13.1 Wearable Injectors: List of Partnerships and Collaborations, 2018-2021
Table 14.1 Wearable Injectors: List of Key Acquisitions, 2000-2023
Table 14.2 Non-Insulin Drug Delivery Devices: Likelihood of Players for Acquisition
Table 14.3 Insulin Delivery Devices: Likelihood of Players for Acquisition
Table 15.1 Patent Analysis: Prominent CPC Symbols
Table 15.2 Patent Analysis: List of Top CPC Symbols
Table 15.3 Patent Analysis: Most Popular CPC Symbols
Table 15.4 Patent Analysis: Summary of Benchmarking Analysis
Table 15.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 15.6 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 16.1 Marketed Drugs: Most Likely Candidates for Delivery via Wearable Injectors
Table 16.2 Marketed Drugs: Likely Candidates for Delivery via Wearable Injectors
Table 16.3 Marketed Drugs: Less Likely Candidates for Delivery via Wearable Injectors
Table 16.4 Marketed Drugs: Least Likely Candidates for Delivery via Wearable Injectors
Table 16.5 Clinical Stage Drugs: Most Likely Candidates for Delivery via Wearable Injectors
Table 16.6 Clinical Stage Drugs: Likely Candidates for Delivery via Wearable Injectors
Table 16.7 Clinical Stage Drugs: Less Likely Candidates for Delivery via Wearable Injectors
Table 16.8 Clinical Stage Drugs: Least Likely Candidates for Delivery via Wearable Injectors
Table 18.1 List of Funding Instances: Information on Company, Year of Funding, Type, Amount Invested and Investors
Table 20.1 List of Contract Manufacturing Organizations
Table 20.2 List of Medical Device Product Design and Development Companies
Table 21.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
Table 21.2 Device Classification: US
Table 21.3 Device Classification: Canada
Table 21.4 Data Requirements and Characteristics of Province-wide HTA Processes in Canada
Table 21.5 Device Classification: Mexico
Table 21.6 Device Classification: Europe
Table 21.7 List of CE Directives in Europe
Table 21.8 Conformity Assessment Modules in Europe
Table 21.9 Device Classification: Australia
Table 21.10 Medical Devices Reimbursement and Pricing Approval Process: Australia
Table 21.11 Device Classification: Brazil
Table 21.12 Device Classification: China
Table 21.13 Device Classification: India
Table 21.14 Device Classification: Japan
Table 21.15 Medical Devices Reimbursement Categories
Table 21.16 Device Classification: Medsafe
Table 21.17 Device Classification: Singapore
Table 21.18 Device Classification: South Korea
Table 21.19 Device Classification: South Africa
Table 21.20 Device Classification: Thailand
Table 21.21 Medical Devices Regulatory Landscape Summary
Table 21.22 Medical Devices Reimbursement Landscape Summary
Table 25.1 Company Snapshot: Company A
Table 25.2 Company Snapshot: Company B
Table 25.3 Company Snapshot: Company C
Table 25.4 Company Snapshot: Company D
Table 25.5 Company Snapshot: Company E
Table 25.6 Company Snapshot: Company F
Table 25.7 Company Snapshot: Company G
Table 25.8 Company Snapshot: Company H
Table 25.9 Company Snapshot: Company I
Table 25.10 Company Snapshot: Company J
Table 34.1 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Table 34.2 Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Table 34.3 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 34.4 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Table 34.5 Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Table 34.6 Wearable Injectors for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Table 34.7 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Table 34.8 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Table 34.9 Wearable Injectors for Non-Insulin Drugs: Distribution by Dose of Drug
Table 34.10 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Table 34.11 Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 34.12 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Container
Table 34.13 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 34.14 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Year of Establishment
Table 34.15 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Company Size
Table 34.16 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Table 34.17 Leading Players: Distribution by Number of Wearable Injectors Developed for Non-Insulin
Table 34.18 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Device
Table 34.19 Drug Device Combinations for Non-Insulin Drugs: Distribution by Status of Development
Table 34.20 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Table 34.21 Drug Device Combinations for Non-Insulin Drugs: Distribution by Usability
Table 34.22 Drug Device Combinations for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Table 34.23 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Table 34.24 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Dose
Table 34.25 Drug Device Combinations for Non-Insulin Drugs: Distribution by Dose of Drug
Table 34.26 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Injection
Table 34.27 Drug Device Combinations for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 34.28 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Container
Table 34.29 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 34.30 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Year of Establishment
Table 34.31 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Company Size
Table 34.32 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Table 34.33 Device Developers: Distribution by Number of Drug Device Combination Developed
Table 34.34 Wearable Injectors for Insulin: Distribution by Type of Device
Table 34.35 Wearable Injectors for Insulin: Distribution by Status of Development
Table 34.36 Wearable Injectors for Insulin: Distribution by Type of Insulin Delivery
Table 34.37 Wearable Injectors for Insulin: Distribution by Type of Automated Insulin Delivery
Table 34.38 Wearable Injectors for Insulin: Distribution by Type of Connectivity Feature
Table 34.39 Wearable Injectors for Insulin: Distribution by Waterproof Capability
Table 34.40 Wearable Injectors for Insulin: Distribution by Usability
Table 34.41 Wearable Injectors for Insulin: Distribution by Period of Use
Table 34.42 Wearable Injectors for Insulin: Distribution by Type of Advanced Feature
Table 34.43 Wearable Injectors for Insulin: Distribution by Type of Drug Container
Table 34.44 Wearable Injectors for Insulin: Distribution by Mode of Drug Filling
Table 34.45 Wearable Injectors for Insulin: Distribution by Type of Dose
Table 34.46 Wearable Injectors for Insulin: Distribution by Type of Diabetes
Table 34.47 Wearable Injectors for Insulin: Distribution by Availability of Connectivity Feature
Table 34.48 Wearable Injectors for Insulin Drug Developers: Distribution by Year of Establishment
Table 34.49 Wearable Injectors for Insulin Drug Developers: Distribution by Company Size
Table 34.50 Wearable Injectors for Insulin Drug Developers: Distribution by Location of Headquarters
Table 34.51 Leading Players: Distribution by Number of Wearable Injectors for Insulin
Table 34.52 Product Competitiveness Analysis: Wearable Injectors for Non-Insulin Drugs
Table 34.53 Product Competitiveness Analysis: Drug Device Combinations for Non-Insulin Drugs
Table 34.54 Product Competitiveness Analysis: Wearable Injectors for Insulin
Table 34.55 Gerresheimer: Annual Revenues, FY 2022 Onwards (EUR Million)
Table 34.56 West Pharmaceuticals: Annual Revenues, FY 2022 Onwards (USD Billion)
Table 34.57 Eli Lilly: Annual Revenues, FY 2022 Onwards (USD Billion)
Table 34.58 Insulet: Annual Revenues, FY 2022 Onwards (USD Million)
Table 34.59 Medtronic: Annual Revenues, FY 2022 Onwards (USD Billion)
Table 34.60 Roche: Annual Revenues, FY 2022 Onwards (CHF Billion)
Table 34.61 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Table 34.62 Partnerships and Collaborations: Distribution by Type of Partnership
Table 34.63 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2015
Table 34.64 Partnerships and Collaborations: Distribution by Partner
Table 34.65 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 34.66 Partnerships and Collaborations: Distribution by Type of Device
Table 34.67 Most Active Players: Distribution by Number of Partnerships
Table 34.68 Most Active Players: Distribution by Type of Partnership
Table 34.69 Partnerships and Collaborations: Local and International Agreements
Table 34.70 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 34.71 Patent Analysis: Distribution by Type of Patent
Table 34.72 Patent Analysis: Distribution by Patent Publication Year
Table 34.73 Patent Analysis: Distribution by Patent Application Year
Table 34.74 Patent Analysis: Distribution by Granted Patents and Patent Applications by Publication Year
Table 34.75 Patent Analysis: Distribution by Jurisdiction
Table 34.76 Patent Analysis: Distribution by Type of Applicant
Table 34.77 Leading Industry Players: Distribution by Number of Patents
Table 34.78 Leading Non-Industry Players: Distribution by Number of Patents
Table 34.79 Leading Individual Assignees: Distribution by Number of Patents
Table 34.80 Patent Analysis: Distribution by Patent Age
Table 34.81 Wearable Injectors: Patent Valuation
Table 34.82 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 34.83 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 34.84 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 34.85 Clinical Trial Analysis: Distribution by Trial Phase
Table 34.86 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 34.87 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Table 34.88 Clinical Trial Analysis: Distribution by Study Design
Table 34.89 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 34.90 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 34.91 Most Active Players: Distribution by Number of Registered Trials
Table 34.92 Most Popular Wearable Injectors: Distribution by Number of Registered Trials
Table 34.93 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 34.94 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Geography
Table 34.95 Funding and Investment Analysis: Distribution of Year of Funding, Since 2014
Table 34.96 Funding and Investment Analysis: Distribution of Amount Invested by Year, Since 2014 (USD Million)
Table 34.97 Funding and Investment Analysis: Distribution by Type of Funding
Table 34.98 Funding and Investment Analysis: Distribution by Type of Device
Table 34.99 Funding and Investment Analysis: Year-wise Distribution by Type of Funding and Amount Raised (USD Million)
Table 34.100 Funding and Investment Analysis: Distribution by Target Disease Indication
Table 34.101 Most Active Players: Distribution by Number of Funding Instances
Table 34.102 Most Active Players: Distribution by Amount Invested
Table 34.103 Leading Investors: Distribution by Number of Funding Instances
Table 34.104 Funding and Investments: Distribution by Geography
Table 34.105 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.106 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.107 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Value)
Table 34.108 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.109 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.110 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Volume)
Table 34.111 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.112 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.113 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Value)
Table 34.114 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.115 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.116 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Volume)
Table 34.117 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.118 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.119 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Value)
Table 34.120 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.121 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.122 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.123 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.124 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.125 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Volume)
Table 34.126 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.127 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.128 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.129 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.130 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.131 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Value)
Table 34.132 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.133 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.134 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.135 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.136 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.137 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Volume)
Table 34.138 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.139 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.140 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.141 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.142 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.143 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.144 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.145 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Value)
Table 34.146 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.147 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.148 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Volume)
Table 34.149 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.150 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.151 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Value)
Table 34.152 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.153 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.154 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Volume)
Table 34.155 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.156 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.157 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Value)
Table 34.158 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.159 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.160 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.161 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.162 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.163 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.164 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.165 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.166 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.167 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.168 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.169 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.170 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.171 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.172 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.173 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.174 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.175 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.176 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.177 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.178 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.179 Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.180 Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.181 Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.182 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Volume)
Table 34.183 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.184 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.185 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.186 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.187 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.188 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.189 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.190 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.191 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.192 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.193 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.194 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.195 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.196 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.197 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.198 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.199 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.200 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.201 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.202 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.203 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Drug Delivery Systems
Figure 6.2 Evolution of Healthcare Safety Legislations
Figure 6.3 Wearable Injectors Market: Key Driving Factors
Figure 6.4 Types of Self-Injection Devices
Figure 7.1 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Figure 7.2 Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Figure 7.3 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 7.4 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Figure 7.5 Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Figure 7.6 Wearable Injectors for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Figure 7.7 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Figure 7.8 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Figure 7.9 Wearable Injectors for Non-Insulin Drugs: Distribution by Dose of Drug
Figure 7.10 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 7.11 Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 7.12 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Container
Figure 7.13 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 7.14 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Year of Establishment
Figure 7.15 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Company Size
Figure 7.16 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Figure 7.17 Leading Players: Distribution by Number of Wearable Injectors Developed for Non-Insulin
Figure 8.1 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Device
Figure 8.2 Drug Device Combinations for Non-Insulin Drugs: Distribution by Status of Development
Figure 8.3 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Figure 8.4 Drug Device Combinations for Non-Insulin Drugs: Distribution by Usability
Figure 8.5 Drug Device Combinations for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Figure 8.6 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Figure 8.7 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Dose
Figure 8.8 Drug Device Combinations for Non-Insulin Drugs: Distribution by Dose of Drug
Figure 8.9 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 8.10 Drug Device Combinations for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 8.11 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Container
Figure 8.12 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 8.13 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Year of Establishment
Figure 8.14 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Company Size
Figure 8.15 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Figure 8.16 Device Developers: Distribution by Number of Drug Device Combination Developed
Figure 9.1 Wearable Injectors for Insulin: Distribution by Type of Device
Figure 9.2 Wearable Injectors for Insulin: Distribution by Status of Development
Figure 9.3 Wearable Injectors for Insulin: Distribution by Type of Insulin Delivery
Figure 9.4 Wearable Injectors for Insulin: Distribution by Type of Automated Insulin Delivery
Figure 9.5 Wearable Injectors for Insulin: Distribution by Type of Connectivity Feature
Figure 9.6 Wearable Injectors for Insulin: Distribution by Waterproof Capability
Figure 9.7 Wearable Injectors for Insulin: Distribution by Usability
Figure 9.8 Wearable Injectors for Insulin: Distribution by Period of Use
Figure 9.9 Wearable Injectors for Insulin: Distribution by Type of Advanced Feature
Figure 9.10 Wearable Injectors for Insulin: Distribution by Type of Drug Container
Figure 9.11 Wearable Injectors for Insulin: Distribution by Mode of Drug Filling
Figure 9.12 Wearable Injectors for Insulin: Distribution by Type of Dose
Figure 9.13 Wearable Injectors for Insulin: Distribution by Type of Diabetes
Figure 9.14 Wearable Injectors for Insulin: Distribution by Availability of Connectivity Feature
Figure 9.15 Wearable Injectors for Insulin Drug Developers: Distribution by Year of Establishment
Figure 9.16 Wearable Injectors for Insulin Drug Developers: Distribution by Company Size
Figure 9.17 Wearable Injectors for Insulin Drug Developers: Distribution by Location of Headquarters
Figure 9.18 Leading Players: Distribution by Number of Wearable Injectors for Insulin
Figure 10.1 Product Competitiveness Analysis: Wearable Injectors for Non-Insulin Drugs
Figure 10.2 Product Competitiveness Analysis: Drug Device Combinations for Non-Insulin Drugs
Figure 10.3 Product Competitiveness Analysis: Wearable Injectors for Insulin
Figure 11.1 Gerresheimer: Annual Revenues, FY 2022 Onwards (EUR Million)
Figure 11.2 West Pharmaceuticals: Annual Revenues, FY 2022 Onwards (USD Billion)
Figure 11.3 Eli Lilly: Annual Revenues, FY 2022 Onwards (USD Billion)
Figure 11.4 Insulet: Annual Revenues, FY 2022 Onwards (USD Million)
Figure 11.5 Medtronic: Annual Revenues, FY 2022 Onwards (USD Billion)
Figure 11.6 Roche: Annual Revenues, FY 2022 Onwards (CHF Billion)
Figure 13.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2015
Figure 13.4 Partnerships and Collaborations: Distribution by Partner
Figure 13.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 13.6 Partnerships and Collaborations: Distribution by Type of Device
Figure 13.7 Most Active Players: Distribution by Number of Partnerships
Figure 13.8 Most Active Players: Distribution by Type of Partnership
Figure 13.9 Partnerships and Collaborations: Local and International Agreements
Figure 13.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 15.1 Patent Analysis: Distribution by Type of Patent
Figure 15.2 Patent Analysis: Distribution by Patent Publication Year
Figure 15.3 Patent Analysis: Distribution by Patent Application Year
Figure 15.4 Patent Analysis: Distribution by Granted Patents and Patent Applications by Publication Year
Figure 15.5 Patent Analysis: Distribution by Jurisdiction
Figure 15.6 Patent Analysis: Distribution by Type of Applicant
Figure 15.7 Patent Analysis: Distribution by CPC Symbols
Figure 15.8 Leading Industry Players: Distribution by Number of Patents
Figure 15.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 15.10 Leading Individual Assignees: Distribution by Number of Patents
Figure 15.11 Patent Benchmarking: Distribution by Patent Characteristics (CPC Symbols)
Figure 15.12 Patent Analysis: Distribution by Patent Age
Figure 15.13 Wearable Injectors: Patent Valuation
Figure 17.1 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 17.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 17.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 17.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 17.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 17.6 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Figure 17.7 Clinical Trial Analysis: Distribution by Study Design
Figure 17.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 17.9 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 17.10 Most Active Players: Distribution by Number of Registered Trials
Figure 17.11 Most Popular Wearable Injectors: Distribution by Number of Registered Trials
Figure 17.12 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 17.13 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Geography
Figure 18.1 Funding and Investment Analysis: Distribution of Year of Funding, Since 2014
Figure 18.2 Funding and Investment Analysis: Distribution of Amount Invested by Year, Since 2014 (USD Million)
Figure 18.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 18.4 Funding and Investment Analysis: Distribution by Type of Device
Figure 18.5 Funding and Investment Analysis: Year-wise Distribution by Type of Funding and Amount Raised (USD Million)
Figure 18.6 Funding and Investment Analysis: Distribution by Target Disease Indication
Figure 18.7 Most Active Players: Distribution by Number of Funding Instances
Figure 18.8 Most Active Players: Distribution by Amount Invested
Figure 18.9 Leading Investors: Distribution by Number of Funding Instances
Figure 18.10 Funding and Investments: Distribution by Geography
Figure 19.1 SWOT Factors: Harvey Ball Analysis
Figure 20.1 CMOs: Distribution by Geography
Figure 21.1 Key Regulatory Authorities for Medical Devices
Figure 21.2 Medical Devices Review / Approval Process in the US
Figure 21.3 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 21.4 Medical Devices National Coverage Determination Process: US
Figure 21.5 Medical Devices Review / Approval Process in Canada
Figure 21.6 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Figure 21.7 Medical Devices Review / Approval Process in Mexico
Figure 21.8 Regulatory Bodies in EU5 Countries
Figure 21.9 Steps involved in CE Marking Process
Figure 21.10 Medical Devices Review / Approval Process in Europe
Figure 21.11 Medical Devices Review / Approval Process in the UK
Figure 21.12 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Figure 21.13 Medical Devices Reimbursement Process: UK
Figure 21.14 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 21.15 Medical Devices Reimbursement Process: France
Figure 21.16 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 21.17 Medical Devices Reimbursement Process for In-Patient Setting: Germany
Figure 21.18 Medical Devices Reimbursement Process for Out-Patient Care: Germany
Figure 21.19 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Figure 21.20 Medical Devices Reimbursement Process: Italy
Figure 21.21 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Figure 21.22 Medical Devices Reimbursement Process: Spain
Figure 21.23 Medical Devices Review / Approval Process in Australia
Figure 21.24 Healthcare Insurance Coverage in Australia: Distribution by Type of Coverage
Figure 21.25 Medical Devices Review / Approval Process in Brazil
Figure 21.26 Medical Devices Reimbursement Process: Brazil
Figure 21.27 Medical Devices Review / Approval Process in China
Figure 21.28 Healthcare Insurance Coverage in China: Distribution by Type of Coverage
Figure 21.29 Medical Devices Reimbursement Process: Shanghai
Figure 21.30 Medical Devices Review / Approval Process in India
Figure 21.31 Healthcare Insurance Coverage in Israel: Distribution by Type of Coverage
Figure 21.32 Medical Devices Review / Approval Process in Japan
Figure 21.33 Medical Devices Reimbursement Process: Japan
Figure 21.34 Healthcare Insurance Coverage in Japan: Distribution by Type of Coverage
Figure 21.35 New Medical Devices Reimbursement Process: Japan
Figure 21.36 Medical Devices Review / Approval Process in New Zealand
Figure 21.37 Healthcare Insurance Coverage in New Zealand: Distribution by Type of Coverage
Figure 21.38 Medical Devices Review / Approval Process in Singapore
Figure 21.39 Medical Devices Review / Approval Process in South Korea
Figure 21.40 Healthcare Insurance Coverage in South Korea: Distribution by Type of Coverage
Figure 21.41 Medical Devices Review / Approval Process in South Africa
Figure 21.42 Medical Devices Review / Approval Process in Taiwan
Figure 21.43 Healthcare Insurance Coverage in Taiwan: Distribution by Type of Coverage
Figure 21.44 Medical Devices Review / Approval Process in Thailand
Figure 21.45 Heat Map Analysis: Comparison of Regional Regulatory Guidelines for Medical Devices
Figure 21.46 Regulatory Control for Medical Devices: Regional Analysis by Device Risk Category
Figure 23.1 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 23.2 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 24.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Value)
Figure 24.2 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 24.3 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 24.4 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Volume)
Figure 24.5 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 24.6 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 25.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Value)
Figure 25.2 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 25.3 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 25.4 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Volume)
Figure 25.5 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 25.6 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Value)
Figure 26.2 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.3 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.4 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.5 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.6 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.7 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Volume)
Figure 26.8 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.9 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.10 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.11 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.12 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Value)
Figure 27.2 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.3 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.4 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.5 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.6 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.7 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Volume)
Figure 27.8 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.9 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.10 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.11 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.12 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.13 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 27.14 Market Movement Analysis: Geographical Regions
Figure 28.1 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 28.2 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 29.1 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Value)
Figure 29.2 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 29.3 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 29.4 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Volume)
Figure 29.5 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 29.6 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 30.1 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Value)
Figure 30.2 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 30.3 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 30.4 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Volume)
Figure 30.5 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 30.6 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.1 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Value)
Figure 31.2 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.3 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.4 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.5 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.6 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.7 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.8 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.9 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.10 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.11 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.12 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.13 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.14 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.15 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.16 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.17 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.18 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.19 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.20 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.21 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.22 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.23 Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.24 Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.25 Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.26 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Volume)
Figure 31.27 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.28 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.29 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.30 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.31 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.32 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.33 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.34 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.35 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.36 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.37 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.38 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.39 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.40 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.41 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.42 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.43 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.44 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.45 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.46 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.47 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.48 Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.49 Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.50 Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.51 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 31.52 Market Movement Analysis: Geographical Regions
Figure 32.1 Concluding Remarks: Market Landscape of Wearable Injectors for Non-Insulin
Figure 32.2 Concluding Remarks: Market Landscape of Drug Device Combinations
Figure 32.3 Concluding Remarks: Market Landscape of Wearable Injectors for Insulin
Figure 32.4 Concluding Remarks: Partnerships and Collaborations
Figure 32.5 Concluding Remarks: Key Acquisition Targets
Figure 32.6 Concluding Remarks: Patent Analysis
Figure 32.7 Concluding Remarks: Likely Drug Candidates
Figure 32.8 Concluding Remarks: Clinical Trial Analysis
Figure 32.9 Concluding Remarks: Funding and Investment Analysis
Figure 32.10 Concluding Remarks: Market Sizing and Opportunity Analysis for Wearable Injectors for Non-Insulin
Figure 32.11 Concluding Remarks: Market Sizing and Opportunity Analysis for Wearable Injectors for Insulinsis